FI110353B - Förfarande för framställning av ett farmaceutiskt preparat i form av en brus- och/eller upplösningstablett eller snabbupplösande granulat - Google Patents
Förfarande för framställning av ett farmaceutiskt preparat i form av en brus- och/eller upplösningstablett eller snabbupplösande granulat Download PDFInfo
- Publication number
- FI110353B FI110353B FI943315A FI943315A FI110353B FI 110353 B FI110353 B FI 110353B FI 943315 A FI943315 A FI 943315A FI 943315 A FI943315 A FI 943315A FI 110353 B FI110353 B FI 110353B
- Authority
- FI
- Finland
- Prior art keywords
- matrix
- active ingredient
- weight
- amount
- parts
- Prior art date
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
- 238000004090 dissolution Methods 0.000 title description 2
- 239000011159 matrix material Substances 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 25
- -1 alkaline earth metal salts Chemical class 0.000 claims abstract description 10
- 239000003792 electrolyte Substances 0.000 claims abstract description 10
- 229960001571 loperamide Drugs 0.000 claims abstract description 9
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920002678 cellulose Polymers 0.000 claims abstract description 8
- 239000001913 cellulose Substances 0.000 claims abstract description 8
- 235000019640 taste Nutrition 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 5
- 238000002844 melting Methods 0.000 claims abstract description 5
- 230000008018 melting Effects 0.000 claims abstract description 5
- 239000007864 aqueous solution Substances 0.000 claims abstract description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract 4
- 150000001340 alkali metals Chemical class 0.000 claims abstract 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims abstract 4
- 150000001805 chlorine compounds Chemical class 0.000 claims abstract 2
- 230000001934 delay Effects 0.000 claims abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 28
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 17
- 229920003136 Eudragit® L polymer Polymers 0.000 claims description 15
- 239000003826 tablet Substances 0.000 claims description 15
- 239000013543 active substance Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 11
- 239000000194 fatty acid Substances 0.000 claims description 11
- 229930195729 fatty acid Natural products 0.000 claims description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
- 235000010355 mannitol Nutrition 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 235000015165 citric acid Nutrition 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229920003137 Eudragit® S polymer Polymers 0.000 claims description 7
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 7
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 6
- 239000000783 alginic acid Substances 0.000 claims description 6
- 235000010443 alginic acid Nutrition 0.000 claims description 6
- 229920000615 alginic acid Polymers 0.000 claims description 6
- 229960001126 alginic acid Drugs 0.000 claims description 6
- 150000004781 alginic acids Chemical class 0.000 claims description 6
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 5
- 239000007938 effervescent tablet Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000001361 adipic acid Substances 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 238000000354 decomposition reaction Methods 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 239000002085 irritant Substances 0.000 claims description 2
- 231100000021 irritant Toxicity 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims 3
- 239000000470 constituent Substances 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 41
- 239000002245 particle Substances 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 2
- 150000002194 fatty esters Chemical class 0.000 abstract 1
- 239000011872 intimate mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000193 polymethacrylate Polymers 0.000 abstract 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 229930195725 Mannitol Natural products 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000594 mannitol Substances 0.000 description 8
- 229960004126 codeine Drugs 0.000 description 7
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 7
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 6
- 229960004993 dimenhydrinate Drugs 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 229920003134 Eudragit® polymer Polymers 0.000 description 5
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 229960001193 diclofenac sodium Drugs 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283153 Cetacea Species 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000019647 acidic taste Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- ZRTWWOONXPFICO-UHFFFAOYSA-N ethyl 2-ethylhexadecanoate Chemical group CCCCCCCCCCCCCCC(CC)C(=O)OCC ZRTWWOONXPFICO-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- KXVSBTJVTUVNPM-UKPNQBOSSA-N loperamide oxide Chemical compound C1([C@]2(O)CC[N@@+](CC2)([O-])CCC(C(=O)N(C)C)(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C(Cl)C=C1 KXVSBTJVTUVNPM-UKPNQBOSSA-N 0.000 description 1
- 229960003954 loperamide oxide Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 235000021400 peanut butter Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Claims (10)
1. Förfarande för framställning av ett farmaceutiskt preparat i form av en brusta- blett och/eller en tablett som sönderfaller i beständsdelar eller ett snabbupplösande granulat, innehällande minst ett aktivt ämne med irriterande smak och minst en ma- tris som fördröjer fiisättandet av aktivt ämne, kännetecknat av att det aktiva ämnet 15 löses med matrisen, som är icke-lösbart eller härt lösbart i vatten, i ett gemensamt, huvudsakligen organiskt lösningsmedel, företrädesvis vid en nägot förhöjd tempera- tur, varvid lösningen med 10-50 viktdelar, företrädesvis 20-40 viktdelar (baserad pä : 1 viktdel av summan av aktivt ämne och matrisöverdrag) anbringas järnnt pä neu- trala bärarämnen och torkas för att avlägsna lösningsmedlet, varpä det erhällna !’·1: 20 granulatet blandas med övriga brus- och /eller sönderfallskomponenter, säväl som aromämnen och liknande och eventuellt pressas tili tabletter, varvid framställningen • · · vid rumstemperatur i vattenbaserad lösning inom frän ca tvä minuter frisätter högst • · · · ,1.·. 65 % företrädesvis högst 50 %, av det aktiva ämnet, dock inom frän maximalt 20 minuter, företrädesvis maximalt 15 minuter, frisätter mer än 70 %, företrädesvis . . 25 minst 80 % av de aktiva ämnena i 0,1 N HC1 vid 38 °C.
"...· 2. Förfarande enligt patentkrav 1, kännetecknat av att matrisen innehäller minst : en fettsyraester och/eller ett vax, företrädesvis med en smältpunkt mellan 30 och -·’ 45 °C, i synnerhet mellan 32 och 35 °C. ;..j
3. Förfarande enligt patentkrav 1 eller 2, kännetecknat av att matrisen innehäl- /.:30 ler minst ett cellulosaderivat, företrädesvis hydroxipropylmetylcellulosaftalat (HPMCP), cellulosaacetatftalat (CAP), cellulosaacetat-trimellitat (CAT), eller cellulosaacetatbutyrat (CAB). 14 110353
4. Förfarande enligt nägot av föregäende patentkrav, kännetecknat av att bärar-ämnet omfattar minst en av ämnena mannit, sorbit, sackaros, mjölksocker, Aerosil, stärkelse, polyvinylpolypyrrolidon, eller en eller flera beständsdelar av brus-syste-men, säsom i synnerhet en ätbar, organisk syra, exempelvis alginsyra, citronsyra, 5 vinsyra eller adipinsyra, eller ätminstone alkalimetall och//eller alkalisk jordartsme-tall ett karbonat och/eller -bikarbonat.
5. Förfarande enligt nägot av föregäende patentkrav, kännetecknat av att det aktiva ämnet blandas i en mängd frän under 60 mg, företrädesvis under 10 mg, med matrisen i en mängd som är en tili tio, företrädesvis tre till fern, ganger mängden av 10 aktivt ämne per tablett eller granulatdos.
6. Förfarande enligt nägot av föregäende patentkrav, för ett aktivt ämne för be-handling av diarre, säsom t.ex loperamid, kännetecknat av att som komplettering tillsätts en blandning, vilken tjänar säsom kompensation för förluster av elektrolyter i kroppen och mängd av salter med alkalimetall och/eller alkalisk jordartsmetall, fö- 15 reträdesvis frän organiska salter, säväl som frän klorider.
7. Förfarande enligt nägot av föregäende patentkrav, kännetecknat av att matrisen dessutom innehäller minst ett av ämnena glukonsyra-deltalakton, citronsyra, •. ·. karbonat eller bikarbonat med alkalimetall eller alkalisk jordartsmetall. • · • · · ·
8. Förfarande enligt nägot av föregäende patentkrav, kännetecknat av att minst * · · • 20 en polymetakrylsyraester, företrädesvis Eudragit L ensam eller i blandning med Eudragit S tillsätts. t · · • 1 · « · · • · · • 1 • · I • · · • · · • · I · t I · » · · t « I · I · t • t * · 1 • · • | · • I I ·
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92100441 | 1992-01-13 | ||
| EP92100441 | 1992-01-13 | ||
| PCT/EP1993/000055 WO1993013760A1 (de) | 1992-01-13 | 1993-01-12 | Pharmazeutische zubereitung in form einer brause- und/oder zerfallstablette oder eines instantgranulats, sowie verfahren zu ihrer herstellung |
| EP9300055 | 1993-01-12 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI943315A0 FI943315A0 (sv) | 1994-07-12 |
| FI943315A FI943315A (sv) | 1994-07-12 |
| FI110353B true FI110353B (sv) | 2002-12-31 |
Family
ID=8209237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI943315A FI110353B (sv) | 1992-01-13 | 1994-07-12 | Förfarande för framställning av ett farmaceutiskt preparat i form av en brus- och/eller upplösningstablett eller snabbupplösande granulat |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5587179A (sv) |
| EP (1) | EP0620731B1 (sv) |
| JP (1) | JPH07506336A (sv) |
| AT (1) | ATE128028T1 (sv) |
| AU (1) | AU668375B2 (sv) |
| CA (1) | CA2127352C (sv) |
| CZ (1) | CZ283351B6 (sv) |
| DE (1) | DE59300632D1 (sv) |
| DK (1) | DK0620731T3 (sv) |
| ES (1) | ES2068800T3 (sv) |
| FI (1) | FI110353B (sv) |
| GR (2) | GR950300005T1 (sv) |
| MX (1) | MX9300110A (sv) |
| PL (1) | PL173676B1 (sv) |
| WO (1) | WO1993013760A1 (sv) |
| ZA (1) | ZA93215B (sv) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5395627A (en) * | 1992-09-04 | 1995-03-07 | Akzo N.V. | Pharmaceutical granulate |
| DE4403943A1 (de) * | 1994-02-08 | 1995-08-10 | Hexal Pharma Gmbh | Orale Azrneimittelzubereitung mit Diclofenac-Natrium |
| TW466119B (en) * | 1994-02-28 | 2001-12-01 | Janssen Pharmaceutica Nv | Film coated tablet of paracetamol and domperidone |
| US5837287A (en) * | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| GB9421836D0 (en) * | 1994-10-28 | 1994-12-14 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms of hydrophobic substances |
| US5807577A (en) * | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
| US6974595B1 (en) * | 1996-05-17 | 2005-12-13 | Proethic Pharmaceuticals, Inc. | Pharmaceutical compositions based on Diclofenae |
| GB9710767D0 (en) * | 1996-06-26 | 1997-07-23 | On Ninh | Analgesic and anti-inflamatory compositions comprising domperidone and methods of using same |
| BE1011045A3 (fr) * | 1997-03-14 | 1999-04-06 | Ucb Sa | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
| US5843477A (en) * | 1997-09-30 | 1998-12-01 | Bayer Corporation | Lubricants for use in tabletting |
| US5904937A (en) * | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
| DE19814256A1 (de) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Feste, schnellzerfallende Cetirizin-Formulierungen |
| DE19814257A1 (de) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Brauseformulierungen |
| DE19822036A1 (de) * | 1998-05-15 | 1999-11-18 | Bayer Ag | Brausezubereitungen |
| GB9816899D0 (en) | 1998-08-05 | 1998-09-30 | Boots Co Plc | Therapeutic agents |
| US7001612B2 (en) | 1998-08-26 | 2006-02-21 | All Sun Hsf Company Limited | Composition for the relief of heat stress |
| US6235322B1 (en) * | 1999-03-09 | 2001-05-22 | Mintech, Inc. | Highly soluble and stable mineral supplements containing calcium and magnesium |
| AU5060499A (en) * | 1999-08-04 | 2001-03-05 | Ranbaxy Laboratories Limited | Hydrodynamically balanced oral drug delivery system |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| NZ521034A (en) * | 2000-02-28 | 2004-08-27 | Vectura Ltd | Improvements in or relating to the delivery of oral drugs |
| WO2001091730A1 (en) | 2000-05-31 | 2001-12-06 | Drugtech Corporation | Mineral supplement |
| GB0222612D0 (en) * | 2002-09-30 | 2002-11-06 | Univ Gent | Controlled delivery system for bioactive substances |
| AU2003282603A1 (en) * | 2002-10-11 | 2004-05-04 | Depomed Development Ltd | Gastro-retentive levodopa delivery form |
| JP4601271B2 (ja) * | 2003-08-01 | 2010-12-22 | 大洋薬品工業株式会社 | 圧縮成形製剤およびその製造方法 |
| US20050089502A1 (en) * | 2003-08-21 | 2005-04-28 | Todd Schansberg | Effervescent delivery system |
| US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| JO3352B1 (ar) * | 2005-06-17 | 2019-03-13 | Apr Applied Pharma Res Sa | صيغ دايكلوفيناك وطرق استخدامه |
| US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
| JP2009517346A (ja) | 2005-11-28 | 2009-04-30 | イメイジノット ピーティーワイ エルティーディー | 治療用化合物の経口送達系 |
| EP1902708A1 (de) | 2006-09-25 | 2008-03-26 | Losan Pharma GmbH | Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung |
| CN101084881B (zh) * | 2007-06-23 | 2012-08-29 | 淮北辉克药业有限公司 | 靶向速释泡腾制剂及其制备方法 |
| RU2482839C2 (ru) | 2007-10-31 | 2013-05-27 | МакНЕЙЛС-ППС, ИНК. | Распадающаяся в полости рта лекарственная форма |
| US8858210B2 (en) | 2009-09-24 | 2014-10-14 | Mcneil-Ppc, Inc. | Manufacture of variable density dosage forms utilizing radiofrequency energy |
| US8871263B2 (en) | 2009-09-24 | 2014-10-28 | Mcneil-Ppc, Inc. | Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| US9445971B2 (en) | 2012-05-01 | 2016-09-20 | Johnson & Johnson Consumer Inc. | Method of manufacturing solid dosage form |
| US9511028B2 (en) | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
| ES2763945T3 (es) | 2013-02-06 | 2020-06-01 | Hermes Arzneimittel Gmbh | Composiciones farmacéuticas que incorporan fármacos en dosis bajas |
| RU2712267C2 (ru) | 2014-01-10 | 2020-01-28 | Джонсон энд Джонсон Консьюмер Инк. | Способ изготовления таблеток с использованием радиочастотного излучения и частиц с поглощающим покрытием |
| HUE051900T2 (hu) | 2014-06-20 | 2021-03-29 | Hermes Arzneimittel Gmbh | Íz-leplezett orális gyógyászati készítmény |
| US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4289751A (en) * | 1979-06-29 | 1981-09-15 | Merck & Co., Inc. | Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof |
| US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
| US4539198A (en) * | 1983-07-07 | 1985-09-03 | Rowell Laboratories, Inc. | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range |
| NL194389C (nl) * | 1984-06-14 | 2002-03-04 | Novartis Ag | Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager. |
| DE3440288C2 (de) * | 1984-11-05 | 1987-03-12 | Gergely, Gerhard, Dr.-Ing., Wien | Pharmazeutische Zubereitung mit einem Gehalt an Ibuprofen sowie Verfahren zu ihrer Herstellung |
| DE3524003A1 (de) * | 1985-07-04 | 1987-01-08 | Heumann Ludwig & Co Gmbh | Arzneimittelgranulat mit verzoegerter wirkstofffreisetzung und verfahren zu seiner herstellung |
| EP0272265B1 (de) * | 1985-09-25 | 1991-05-22 | Gergely, Gerhard, Dr. | Zerfallstablette und verfahren zu ihrer herstellung |
| US4753800A (en) * | 1985-10-04 | 1988-06-28 | Warner-Lambert Company | Medicament adsorbates and their preparation |
| NZ231281A (en) * | 1988-11-08 | 1991-01-29 | Takeda Chemical Industries Ltd | Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol |
| GB8908361D0 (en) * | 1989-04-13 | 1989-06-01 | Beecham Group Plc | Composition |
-
1993
- 1993-01-11 MX MX9300110A patent/MX9300110A/es not_active IP Right Cessation
- 1993-01-12 DK DK93902180.4T patent/DK0620731T3/da active
- 1993-01-12 WO PCT/EP1993/000055 patent/WO1993013760A1/de active IP Right Grant
- 1993-01-12 ES ES93902180T patent/ES2068800T3/es not_active Expired - Lifetime
- 1993-01-12 JP JP5512137A patent/JPH07506336A/ja active Pending
- 1993-01-12 CA CA002127352A patent/CA2127352C/en not_active Expired - Fee Related
- 1993-01-12 US US08/256,503 patent/US5587179A/en not_active Expired - Lifetime
- 1993-01-12 DE DE59300632T patent/DE59300632D1/de not_active Expired - Lifetime
- 1993-01-12 PL PL93304677A patent/PL173676B1/pl not_active IP Right Cessation
- 1993-01-12 CZ CZ941605A patent/CZ283351B6/cs not_active IP Right Cessation
- 1993-01-12 EP EP93902180A patent/EP0620731B1/de not_active Expired - Lifetime
- 1993-01-12 AU AU33492/93A patent/AU668375B2/en not_active Ceased
- 1993-01-12 AT AT93902180T patent/ATE128028T1/de active
- 1993-01-13 ZA ZA93215A patent/ZA93215B/xx unknown
-
1994
- 1994-07-12 FI FI943315A patent/FI110353B/sv active
-
1995
- 1995-02-28 GR GR950300005T patent/GR950300005T1/el unknown
- 1995-10-18 GR GR950402909T patent/GR3017806T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX9300110A (es) | 1994-07-29 |
| EP0620731A1 (de) | 1994-10-26 |
| ATE128028T1 (de) | 1995-10-15 |
| GR950300005T1 (en) | 1995-02-28 |
| ZA93215B (en) | 1993-08-19 |
| ES2068800T3 (es) | 1995-12-16 |
| AU668375B2 (en) | 1996-05-02 |
| EP0620731B1 (de) | 1995-09-20 |
| AU3349293A (en) | 1993-08-03 |
| FI943315A0 (sv) | 1994-07-12 |
| ES2068800T1 (es) | 1995-05-01 |
| DE59300632D1 (de) | 1995-10-26 |
| CA2127352A1 (en) | 1993-07-22 |
| DK0620731T3 (da) | 1996-04-09 |
| PL173676B1 (pl) | 1998-04-30 |
| CZ283351B6 (cs) | 1998-03-18 |
| FI943315A (sv) | 1994-07-12 |
| US5587179A (en) | 1996-12-24 |
| CZ160594A3 (en) | 1994-12-15 |
| JPH07506336A (ja) | 1995-07-13 |
| WO1993013760A1 (de) | 1993-07-22 |
| CA2127352C (en) | 2005-05-31 |
| GR3017806T3 (en) | 1996-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI110353B (sv) | Förfarande för framställning av ett farmaceutiskt preparat i form av en brus- och/eller upplösningstablett eller snabbupplösande granulat | |
| US5891476A (en) | Tastemasked pharmaceutical system | |
| CA2375600C (fr) | Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif | |
| FI111333B (sv) | Fast lyofiliserad beredningsform och dess framställning | |
| CA2771053C (fr) | Microgranules flottants | |
| KR100358211B1 (ko) | 발포시스템및제약활성물질을함유하는과립제품이나정제와그제조방법 | |
| JPH08503482A (ja) | 部分水素添加植物油で被覆されたシメチジン顆粒剤 | |
| CH650674A5 (fr) | Poudre a base de sel d'addition d'acide de bacampicilline micro-encapsule et composition pharmaceutique la contenant. | |
| HRP20010463A2 (en) | Controlled release galantamine composition | |
| EP2275141A1 (en) | Tastemasked pharmaceutical compositions | |
| HU198621B (en) | Process for producing easily administrable pharmaceutical compositions comprising antibacterial active ingredient, with regulated release of active ingredient | |
| JP2003528914A (ja) | カルベジロールの濃縮溶液 | |
| EP2983650B1 (en) | Oral pharmaceutical composition comprising taste-masked n-acetylcysteine | |
| WO2013024373A1 (en) | Pharmaceutical composition comprising cefuroxime | |
| CA2452239C (fr) | Formulation pharmaceutique au gout masque et son procede de preparation | |
| KR20010090830A (ko) | 코팅된 과립 결정성 이부프로펜 입자 | |
| JP4808392B2 (ja) | 苦味を隠蔽する薬理組成物 | |
| CA2250524A1 (en) | Effervescent formulation containing plant extract | |
| JPH06340534A (ja) | 新規なラフト形成性制酸調合剤 | |
| WO2003059349A1 (en) | Sedative non-benzodiazepine formulations | |
| EP3154512B1 (en) | Solid oral formulations comprising solid melt dispersions of organic acids in xylitol | |
| JPH11349492A (ja) | 苦味を低減した経口用医薬組成物および苦味低減化方法 | |
| JPS634803B2 (sv) |
